Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study)

Authors

Satoshi Ito
Tomonori Ishii (ORCID: https://orcid.org/0000-0001-5361-5824)
Katsuya Suzuki (ORCID: https://orcid.org/0009-0008-2930-5365)
Hiroaki Taguchi (ORCID: https://orcid.org/0000-0003-3183-6380)
Kei Ikeda (ORCID: https://orcid.org/0000-0003-0574-9611)
Mitsuhiro Akiyama (ORCID: https://orcid.org/0000-0001-5075-8977)
Yuko Kaneko (ORCID: https://orcid.org/0000-0003-2646-5765)
Toshihiko Hidaka (ORCID: https://orcid.org/0000-0002-9919-1964)
Shintaro Hirata (ORCID: https://orcid.org/0000-0002-2474-9943)
Shuji Asai (ORCID: https://orcid.org/0000-0002-4030-8793)
Naoki Kato
Motohide Kaneko

Institutions

Keio University (JP)
Tokyo Medical Center (JP)
Hiroshima University Hospital (JP)
Kaneka (Japan) (JP)
University of Miyazaki Hospital (JP)
Kawasaki Hospital (JP)
Foundation for Biomedical Research and Innovation (JP)
Nagoya University (JP)
Dokkyo Medical University (JP)
Tohoku Medical and Pharmaceutical University (JP)

Publication Details

Journal: PLoS ONE
Published: 2025-05-19
DOI: https://doi.org/10.1371/journal.pone.0322621
Primary Topic: Chronic Lymphocytic Leukemia Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study)

Satoshi Ito, Tomonori Ishii, Katsuya Suzuki, Hiroaki Taguchi et al.

May 19, 2025

1 links

PLoS ONE

Chronic Lymphocytic Leukemia Research

article

Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study)

Satoshi Ito, Tomonori Ishii, Katsuya Suzuki, Hiroaki Taguchi, Kei Ikeda, Mitsuhiro Akiyama, Yuko Kaneko, Toshihiko Hidaka, Shintaro Hirata, Shuji Asai, Naoki Kato, Motohide Kaneko

May 19, 2025article en

Abstract

No abstract available for this paper.

PLoS ONEVol. 20(5)

Keio University (JP), Tokyo Medical Center (JP), Hiroshima University Hospital (JP), Kaneka (Japan) (JP), University of Miyazaki Hospital (JP), Kawasaki Hospital (JP), Foundation for Biomedical Research and Innovation (JP), Nagoya University (JP), Dokkyo Medical University (JP), Tohoku Medical and Pharmaceutical University (JP)

Reduced inequalities

Openalex Percentile: Top 84%

Chronic Lymphocytic Leukemia Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.